MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/s1473-3099(20)30847-1

Медицинская библиотека · The Lancet. Infectious diseases · 2020

Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance.

Koehler Philipp, Bassetti Matteo, Chakrabarti Arunaloke, Chen Sharon C A, Colombo Arnaldo Lopes, Hoenigl Martin, Klimko Nikolay, Lass-Flörl Cornelia, Oladele Rita O, Vinh Donald C, Zhu Li-Ping, Böll Boris, Brüggemann Roger, Gangneux Jean-Pierre, Perfect John R, Patterson Thomas F, Persigehl Thorsten, Meis Jacques F, Ostrosky-Zeichner Luis, White P Lewis, Verweij Paul E, Cornely Oliver A, European Confederation of Medical Mycology, International Society for Human Animal Mycology, Asia Fungal Working Group, INFOCUS LATAM/ISHAM Working Group, ISHAM Pan Africa Mycology Working Group, European Society for Clinical Microbiology, Infectious Diseases Fungal Infection Study Group, ESCMID Study Group for Infections in Critically Ill Patients, Interregional Association of Clinical Microbiology and Antimicrobial Chemotherapy, Medical Mycology Society of Nigeria, Medical Mycology Society of China Medicine Education Association, Infectious Diseases Working Party of the German Society for Haematology and Medical Oncology, Association of Medical Microbiology, Infectious Disease Canada

СтатьяОбзорConsensus StatementПеревод пока не подготовлен

Аннотация

Severe acute respiratory syndrome coronavirus 2 causes direct damage to the airway epithelium, enabling aspergillus invasion. Reports of COVID-19-associated pulmonary aspergillosis have raised concerns about it worsening the disease course of COVID-19 and increasing mortality. Additionally, the first cases of COVID-19-associated pulmonary aspergillosis caused by azole-resistant aspergillus have been reported. This article constitutes a consensus statement on defining and managing COVID-19-associated pulmonary aspergillosis, prepared by experts and endorsed by medical mycology societies. COVID-19-associated pulmonary aspergillosis is proposed to be defined as possible, probable, or proven on the basis of sample validity and thus diagnostic certainty. Recommended first-line therapy is either voriconazole or isavuconazole. If azole resistance is a concern, then liposomal amphotericin B is the drug of choice. Our aim is to provide definitions for clinical research and up-to-date recommendations for clinical management of the diagnosis and treatment of COVID-19-associated pulmonary aspergillosis.

Для цитирования: Koehler Philipp, Bassetti Matteo, Chakrabarti Arunaloke, Chen Sharon C A, Colombo Arnaldo Lopes, Hoenigl Martin, Klimko Nikolay, Lass-Flörl Cornelia, Oladele Rita O, Vinh Donald C, Zhu Li-Ping, Böll Boris, Brüggemann Roger, Gangneux Jean-Pierre, Perfect John R, Patterson Thomas F, Persigehl Thorsten, Meis Jacques F, Ostrosky-Zeichner Luis, White P Lewis, Verweij Paul E, Cornely Oliver A, European Confederation of Medical Mycology, International Society for Human Animal Mycology, Asia Fungal Working Group, INFOCUS LATAM/ISHAM Working Group, ISHAM Pan Africa Mycology Working Group, European Society for Clinical Microbiology, Infectious Diseases Fungal Infection Study Group, ESCMID Study Group for Infections in Critically Ill Patients, Interregional Association of Clinical Microbiology and Antimicrobial Chemotherapy, Medical Mycology Society of Nigeria, Medical Mycology Society of China Medicine Education Association, Infectious Diseases Working Party of the German Society for Haematology and Medical Oncology, Association of Medical Microbiology, Infectious Disease Canada. Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance.. The Lancet. Infectious diseases. 2020. DOI: 10.1016/s1473-3099(20)30847-1.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.